Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease
Identifieur interne : 001933 ( Istex/Curation ); précédent : 001932; suivant : 001934Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease
Auteurs : Theresa A. Zesiewicz [États-Unis] ; Kelly L. Sullivan [États-Unis] ; John L. Maldonado [États-Unis] ; William O. Tatum [États-Unis] ; Robert A. Hauser [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-09.
English descriptors
- KwdEn :
Abstract
We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; P = 0.02). Percent on time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20563
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001933
Links to Exploration step
ISTEX:9C448C47012553C0CA49E602AB1F33011679209CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Maldonado, John L" sort="Maldonado, John L" uniqKey="Maldonado J" first="John L." last="Maldonado">John L. Maldonado</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>College of Public Health, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>College of Public Health, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Tatum, William O" sort="Tatum, William O" uniqKey="Tatum W" first="William O." last="Tatum">William O. Tatum</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9C448C47012553C0CA49E602AB1F33011679209C</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20563</idno><idno type="url">https://api.istex.fr/document/9C448C47012553C0CA49E602AB1F33011679209C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001933</idno><idno type="wicri:Area/Istex/Curation">001933</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Maldonado, John L" sort="Maldonado, John L" uniqKey="Maldonado J" first="John L." last="Maldonado">John L. Maldonado</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>College of Public Health, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>College of Public Health, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Tatum, William O" sort="Tatum, William O" uniqKey="Tatum W" first="William O." last="Tatum">William O. Tatum</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-09">2005-09</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1205">1205</biblScope><biblScope unit="page" to="1209">1209</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9C448C47012553C0CA49E602AB1F33011679209C</idno><idno type="DOI">10.1002/mds.20563</idno><idno type="ArticleID">MDS20563</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Keppra</term><term>Parkinson's disease</term><term>dyskinesia</term><term>levetiracetam</term><term>levodopa</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; P = 0.02). Percent on time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001933 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001933 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:9C448C47012553C0CA49E602AB1F33011679209C
|texte= Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |